Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alvotech Starts European Trial For High-Concentration Adalimumab

Executive Summary

Icelandic developer Alvotech is looking to set itself apart from the pack offering biosimilar rivals to Humira by conducting a Phase III clinical trial for an alternative to AbbVie’s high-concentration 100mg/ml version of adalimumab, the world’s best-selling drug.

You may also be interested in...



Alvotech Moves Ahead On Higher-Concentration Humira Rival

Alvotech is moving ahead with developing its higher-concentration adalimumab biosimilar after completing enrollment in a European Phase III trial.

Nichi-Iko Looks To File For Interchangeable Infliximab In US Next Year

With a US filing for interchangeable infliximab scheduled for next year, Nichi-Iko is lining up a launch of etanercept in Japan as it seeks alliances to broaden its biosimilars pipeline.

Alvotech And Fuji Stretch Alliance To Ustekinumab In Japan

Alvotech and Fuji Pharma have extended their alliance to cover exclusive development and supply of biosimilar ustekinumab in Japan. 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB140170

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel